Kadimastem Ltd. Logo

Kadimastem Ltd.

Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.

KDST | TA

Overview

Corporate Details

ISIN(s):
IL0011284614
LEI:
Country:
Israel
Address:
Pinchas Sapir 3, Weizmann Science Park, 7414003 Nes-Ziona
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kadimastem Ltd. is a clinical-stage biotechnology company specializing in the development of regenerative medicine and cell therapies. The company leverages a proprietary technology platform for the industrial development and manufacturing of "off-the-shelf," allogeneic cell products derived from human embryonic stem cells. These therapies are designed for broad patient application to treat debilitating diseases, with a focus on conditions such as diabetes and neurodegenerative disorders. Kadimastem's approach aims to provide commercially viable, readily available treatments by creating universal cell-based products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-05-28 11:41
Investor Presentation
Company Presentation
English 4.4 MB
2024-05-28 11:41
Pre-Annual General Meeting Information
Company Presentation
Russian 42.5 KB
2024-02-12 13:47
Regulatory News Service
Excellence Investments Management and Securities will cease to operate as a mar…
Hebrew (modern) 122.7 KB
2022-12-13 16:05
Regulatory News Service
Rights Offering and Identifying Details for New Security-KADIMASTEM R4
Hebrew (modern) 177.9 KB
2022-08-09 13:00
Regulatory News Service
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
English 12.0 KB
2022-06-08 13:00
Regulatory News Service
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards …
English 12.1 KB
2022-05-30 15:10
Regulatory News Service
Kadimastem Awarded Patent in Japan for AstroRx For ALS and Drug Screening
English 10.6 KB
2022-05-18 13:00
Regulatory News Service
Kadimastem Expands R&D Program to Include Multiple Sclerosis
English 9.5 KB
2022-03-03 14:05
Regulatory News Service
Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) f…
English 10.4 KB
2021-12-13 13:00
Capital/Financing Update
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel I…
English 10.6 KB
2021-10-26 07:49
Share Issue/Capital Change
Kadimastem Raises $5 million In Private Placement
English 10.5 KB
2021-10-25 14:09
Share Issue/Capital Change
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
English 10.5 KB
2021-10-12 15:55
Legal Proceedings Report
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regar…
English 9.5 KB
2021-05-02 19:15
Investor Presentation
Company Presentation May 2021
English 3.0 MB
2021-05-02 19:15
Report Publication Announcement
Company Presentation May 2021
Russian 42.5 KB

Automate Your Workflow. Get a real-time feed of all Kadimastem Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Kadimastem Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.